HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CASR
calcium sensing receptor
Chromosome 3 Β· 3q13.33-q21.1
NCBI Gene: 846Ensembl: ENSG00000036828.18HGNC: HGNC:1514UniProt: P41180
535PubMed Papers
24Diseases
7Drugs
313Pathogenic Variants
FUNCTIONAL ROLE
Receptor
RESEARCH IMPACT
Highly StudiedTrendingVariant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
intracellular calcium ion homeostasisG protein-coupled receptor signaling pathwaypositive regulation of NLRP3 inflammasome complex assemblyadenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayfamilial hypocalciuric hypercalcemia 1autosomal dominant hypocalcemia 1Familial hypocalciuric hypercalcemia type 1neonatal severe primary hyperparathyroidism
✦AI Summary

The calcium-sensing receptor (CASR) is a G-protein-coupled receptor that detects extracellular calcium concentration fluctuations and maintains calcium homeostasis 1. CASR functions as a homodimer with an extracellular Venus Flytrap domain containing calcium-binding sites and a seven-transmembrane domain 2. The receptor employs a co-agonist mechanism, with aromatic amino acids like tryptophan acting with divalent cations (calcium or magnesium) to achieve full activation 3. CASR demonstrates promiscuous G-protein coupling, binding Gq, Gi, and Gs proteins through a common mode involving intracellular loops and the C-terminal helix 1. In parathyroid glands and kidney, elevated circulating calcium activates CASR, suppressing parathyroid hormone (PTH) secretion and regulating renal tubular calcium resorption 4. Dysfunction of CASR causes multiple disorders: gain-of-function mutations cause autosomal dominant hypocalcemia, while loss-of-function mutations lead to familial hypocalciuric hypercalcemia 5. Recent evidence identifies CASR signaling through diacylglycerol kinase Ξ΄ (DGKD) as a key pathway in kidney stone disease susceptibility; reduced CaSR signaling increases stone risk, potentially reversible by calcimimetic drugs 6.

Sources cited
1
CASR couples promiscuously to Gq, Gi, and Gs G-proteins through a common binding mode involving intracellular loops and C-terminal regions
PMID: 38632411
2
L-tryptophan acts as a co-agonist with calcium to activate CASR through binding to the 7-transmembrane domain
PMID: 38326620
3
CASR structural features include N-terminal signal peptide, extracellular Venus Flytrap domain with calcium-binding sites, and seven-transmembrane domain
PMID: 23856260
4
CASR is expressed in parathyroid glands, stomach, intestine, and kidney where it regulates calcium homeostasis and PTH secretion
PMID: 29101653
5
Parathyroid glands sense extracellular calcium through CASR and adjust PTH release to maintain physiological calcium concentration
PMID: 27816765
6
CASR signaling through DGKD partner protein affects kidney stone disease risk; reduced CaSR signaling increases susceptibility, reversible by cinacalcet
PMID: 40372791
Disease Associationsβ“˜24
familial hypocalciuric hypercalcemia 1Open Targets
0.85Strong
autosomal dominant hypocalcemia 1Open Targets
0.84Strong
Familial hypocalciuric hypercalcemia type 1Open Targets
0.82Strong
neonatal severe primary hyperparathyroidismOpen Targets
0.81Strong
Familial isolated hypoparathyroidismOpen Targets
0.80Strong
autosomal dominant hypocalcemiaOpen Targets
0.72Strong
familial hypocalciuric hypercalcemiaOpen Targets
0.68Moderate
hyperparathyroidismOpen Targets
0.68Moderate
nephrolithiasisOpen Targets
0.67Moderate
generalised epilepsyOpen Targets
0.67Moderate
parathyroid diseaseOpen Targets
0.63Moderate
secondary hyperparathyroidismOpen Targets
0.60Moderate
chronic kidney diseaseOpen Targets
0.59Moderate
nephrocalcinosisOpen Targets
0.55Moderate
Parathyroid Gland CarcinomaOpen Targets
0.54Moderate
HypercalcemiaOpen Targets
0.51Moderate
mineral metabolism diseaseOpen Targets
0.50Moderate
Bartter syndrome with hypocalcemiaOpen Targets
0.48Moderate
type 2 diabetes mellitusOpen Targets
0.47Moderate
genetic disorderOpen Targets
0.42Moderate
Epilepsy, idiopathic generalized 8UniProt
Hyperparathyroidism, neonatal severeUniProt
Hypocalcemia, autosomal dominant 1UniProt
Hypocalciuric hypercalcemia, familial 1UniProt
Pathogenic Variants313
NM_000388.4(CASR):c.680G>A (p.Arg227Gln)Pathogenic
Familial hypocalciuric hypercalcemia 1|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1|not provided|Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia 1;Autosomal dominant hypocalcemia 1;Epilepsy, idiopathic generalized, susceptibility to, 8;Neonatal severe primary hyperparathyroidism|CASR-related disorder|Nephrolithiasis/nephrocalcinosis
β˜…β˜…β˜†β˜†2026β†’ Residue 227
NM_000388.4(CASR):c.164C>T (p.Pro55Leu)Pathogenic
not provided|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia|Nephrolithiasis/nephrocalcinosis|Familial hypocalciuric hypercalcemia 1
β˜…β˜…β˜†β˜†2026β†’ Residue 55
NM_000388.4(CASR):c.658C>T (p.Arg220Trp)Pathogenic
not provided|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|Neonatal severe primary hyperparathyroidism;Epilepsy, idiopathic generalized, susceptibility to, 8;Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia 1|Neonatal severe primary hyperparathyroidism|Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia 1
β˜…β˜…β˜†β˜†2026β†’ Residue 220
NM_000388.4(CASR):c.157T>C (p.Ser53Pro)Pathogenic
Familial hypocalciuric hypercalcemia|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2026β†’ Residue 53
NM_000388.4(CASR):c.554G>A (p.Arg185Gln)Pathogenic
Familial hypocalciuric hypercalcemia 1|Neonatal severe primary hyperparathyroidism|not provided|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1|Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia 1;Autosomal dominant hypocalcemia 1;Epilepsy, idiopathic generalized, susceptibility to, 8;Neonatal severe primary hyperparathyroidism|CASR-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 185
NM_000388.4(CASR):c.197G>A (p.Arg66His)Pathogenic
Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|not provided|Nephrolithiasis/nephrocalcinosis|Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025β†’ Residue 66
NM_000388.4(CASR):c.659G>A (p.Arg220Gln)Pathogenic
not provided|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia 1|Autosomal dominant hypocalcemia 1
β˜…β˜…β˜†β˜†2025β†’ Residue 220
NM_000388.4(CASR):c.2182G>T (p.Val728Phe)Pathogenic
Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|not provided|Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025β†’ Residue 728
NM_000388.4(CASR):c.2024G>A (p.Trp675Ter)Pathogenic
Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1
β˜…β˜…β˜†β˜†2025β†’ Residue 675
NM_000388.4(CASR):c.2657G>C (p.Arg886Pro)Pathogenic
not provided|Familial hypocalciuric hypercalcemia 1|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025β†’ Residue 886
NM_000388.4(CASR):c.1378_1379insAGCAAAGGPathogenic
not provided|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025
NM_000388.4(CASR):c.2361CTT[2] (p.Phe790del)Pathogenic
Autosomal dominant hypocalcemia|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025β†’ Residue 790
NM_000388.4(CASR):c.679C>T (p.Arg227Ter)Pathogenic
Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|not provided|Neonatal severe primary hyperparathyroidism;Familial hypocalciuric hypercalcemia 1;Epilepsy, idiopathic generalized, susceptibility to, 8;Autosomal dominant hypocalcemia 1
β˜…β˜…β˜†β˜†2025β†’ Residue 227
NM_000388.4(CASR):c.2038C>T (p.Arg680Cys)Pathogenic
not provided|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia|Autosomal dominant hypocalcemia 1;Neonatal severe primary hyperparathyroidism;Epilepsy, idiopathic generalized, susceptibility to, 8;Familial hypocalciuric hypercalcemia 1
β˜…β˜…β˜†β˜†2025β†’ Residue 680
NM_000388.4(CASR):c.73C>T (p.Arg25Ter)Pathogenic
not provided|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1|CASR-related calcium metabolism disorders|Nephrolithiasis/nephrocalcinosis|Autosomal dominant hypocalcemia 1|Neonatal severe primary hyperparathyroidism|Familial hypocalciuric hypercalcemia 1;Neonatal severe primary hyperparathyroidism;Autosomal dominant hypocalcemia 1;Epilepsy, idiopathic generalized, susceptibility to, 8|Familial hypocalciuric hypercalcemia 1
β˜…β˜…β˜†β˜†2025β†’ Residue 25
NM_000388.4(CASR):c.2405A>G (p.Asn802Ser)Pathogenic
not provided|Autosomal dominant hypocalcemia 1;Familial hypocalciuric hypercalcemia|Autosomal dominant hypocalcemia 1;Epilepsy, idiopathic generalized, susceptibility to, 8;Familial hypocalciuric hypercalcemia 1;Neonatal severe primary hyperparathyroidism|CASR-related disorder|Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025β†’ Residue 802
NM_000388.4(CASR):c.428G>A (p.Gly143Glu)Pathogenic
Familial hypocalciuric hypercalcemia 1|not provided|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1|Familial hypocalciuric hypercalcemia
β˜…β˜…β˜†β˜†2025β†’ Residue 143
NM_000388.4(CASR):c.440C>T (p.Ser147Leu)Likely pathogenic
not provided|Familial hyperparathyroidism or Hypocalciuric hypercalcaemia
β˜…β˜…β˜†β˜†2025β†’ Residue 147
NM_000388.4(CASR):c.1664T>C (p.Ile555Thr)Pathogenic
not provided|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1|Familial hypocalciuric hypercalcemia|Nephrolithiasis/nephrocalcinosis
β˜…β˜…β˜†β˜†2025β†’ Residue 555
NM_000388.4(CASR):c.2065G>A (p.Val689Met)Pathogenic
Familial hypocalciuric hypercalcemia|Familial hypocalciuric hypercalcemia;Autosomal dominant hypocalcemia 1|not provided|Epilepsy, idiopathic generalized, susceptibility to, 8;Familial hypocalciuric hypercalcemia 1;Neonatal severe primary hyperparathyroidism;Autosomal dominant hypocalcemia 1
β˜…β˜…β˜†β˜†2025β†’ Residue 689
View on ClinVar β†—
Drug Targets7
ASP7991Phase II
Calcium sensing receptor positive allosteric modulator
hyperparathyroidism
CINACALCETApproved
Calcium sensing receptor positive allosteric modulator
hyperparathyroidism
CINACALCET HYDROCHLORIDEApproved
Calcium sensing receptor positive allosteric modulator
secondary hyperparathyroidism
ETELCALCETIDEApproved
Calcium sensing receptor agonist
secondary hyperparathyroidism
ETELCALCETIDE HYDROCHLORIDEApproved
Calcium sensing receptor agonist
secondary hyperparathyroidism
EVOCALCETApproved
Calcium sensing receptor positive allosteric modulator
secondary hyperparathyroidism
RONACALERETPhase II
Calcium sensing receptor antagonist
osteoporosis
Related Genes
GNAI1Protein interaction99%GNA11Protein interaction98%PTHProtein interaction98%PLCB4Protein interaction97%GNAQProtein interaction97%PLCB1Protein interaction97%
Tissue Expression6 tissues
Ovary
100%
Liver
81%
Brain
37%
Bone Marrow
25%
Lung
3%
Heart
0%
Gene Interaction Network
Click a node to explore
CASRGNAI1GNA11PTHPLCB4GNAQPLCB1
PROTEIN STRUCTURE
Preparing viewer…
PDB5FBK Β· 2.10 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.47Moderately Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.33 [0.24–0.47]
RankingsWhere CASR stands among ~20K protein-coding genes
  • #469of 20,598
    Most Researched535 Β· top 5%
  • #281of 1,025
    FDA-Approved Drug Targets5
  • #194of 5,498
    Most Pathogenic Variants313 Β· top 5%
  • #2,685of 17,882
    Most Constrained (LOEUF)0.47 Β· top quartile
Genes detectedCASR
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
Secretory diarrhoea: mechanisms and emerging therapies.
PMID: 26122478
Nat Rev Gastroenterol Hepatol Β· 2015
1.00
2
Allosteric modulation and G-protein selectivity of the Ca
PMID: 38326620
Nature Β· 2024
0.90
3
A calcium-sensing receptor allelic series and underdiagnosis of genetically driven hypocalcemia.
PMID: 40664210
Am J Hum Genet Β· 2025
0.84
4
[Not Available].
PMID: 29157484
Ann Endocrinol (Paris) Β· 2017
0.82
5
Promiscuous G-protein activation by the calcium-sensing receptor.
PMID: 38632411
Nature Β· 2024
0.80